Cyclin-dependent kinase inhibitors in brain cancer: current state and future directions.
Cyclin-dependent kinases
clinical trials
cyclin-dependent kinase inhibitors
glioblastoma
gliomas
resistance
Journal
Cancer drug resistance (Alhambra, Calif.)
ISSN: 2578-532X
Titre abrégé: Cancer Drug Resist
Pays: United States
ID NLM: 101738710
Informations de publication
Date de publication:
2020
2020
Historique:
received:
05
11
2019
revised:
11
12
2019
accepted:
20
12
2019
entrez:
18
5
2022
pubmed:
19
3
2020
medline:
19
3
2020
Statut:
epublish
Résumé
Cyclin-dependent kinases (CDKs) are important regulatory enzymes in the normal physiological processes that drive cell-cycle transitions and regulate transcription. Virtually all cancers harbour genomic alterations that lead to the constitutive activation of CDKs, resulting in the proliferation of cancer cells. CDK inhibitors (CKIs) are currently in clinical use for the treatment of breast cancer, combined with endocrine therapy. In this review, we describe the potential of CKIs for the treatment of cancer with specific focus on glioblastoma (GBM), the most common and aggressive primary brain tumour in adults. Despite intense effort to combat GBM with surgery, radiation and temozolomide chemotherapy, the median survival for patients is 15 months and the majority of patients experience disease recurrence within 6-8 months of treatment onset. Novel therapeutic approaches are urgently needed for both newly diagnosed and recurrent GBM patients. In this review, we summarise the current preclinical and clinical findings emphasising that CKIs could represent an exciting novel approach for GBM treatment.
Identifiants
pubmed: 35582046
doi: 10.20517/cdr.2019.105
pmc: PMC9094053
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
48-62Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
All authors declared that there are no conflicts of interest.
Références
Proc Natl Acad Sci U S A. 1992 Sep 1;89(17):7900-4
pubmed: 1518810
Biomed Res Int. 2014;2014:869269
pubmed: 25136634
J Neurooncol. 2013 Nov;115(2):169-78
pubmed: 23943501
Apoptosis. 2014 Apr;19(4):629-42
pubmed: 24213561
J Clin Neurosci. 2015 Aug;22(8):1219-26
pubmed: 25957782
Cell Death Differ. 2012 Dec;19(12):1950-61
pubmed: 22743999
Oncologist. 2015 May;20(5):483-90
pubmed: 25876993
Nat Rev Cancer. 2009 Mar;9(3):153-66
pubmed: 19238148
Neuro Oncol. 1999 Jan;1(1):44-51
pubmed: 11550301
Oncotarget. 2017 Mar 7;8(10):17373-17382
pubmed: 28077789
Mol Cancer. 2008 May 20;7:41
pubmed: 18492260
Gene. 2004 Aug 4;337:15-23
pubmed: 15276198
Cancer Chemother Pharmacol. 2019 Aug;84(2):447-452
pubmed: 31079218
Oncogene. 1999 Jan 28;18(4):1093-102
pubmed: 10023686
Cell Cycle. 2010 Jan 1;9(1):168-78
pubmed: 20016283
Mol Cell Biol. 1995 May;15(5):2536-46
pubmed: 7739537
Oncotarget. 2015 Mar 30;6(9):7318-24
pubmed: 25821160
J Biol Chem. 2002 Jul 12;277(28):25465-73
pubmed: 11980906
Biochem Biophys Res Commun. 1994 Jun 15;201(2):589-95
pubmed: 8002990
Oncogene. 2004 Jan 15;23(2):446-56
pubmed: 14724573
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Mech Ageing Dev. 2008 Jul-Aug;129(7-8):391-407
pubmed: 18406444
Sci Rep. 2016 Jul 05;6:29090
pubmed: 27378523
Oncogene. 2012 Sep 20;31(38):4207-20
pubmed: 22179826
Virus Res. 2002 Nov;89(2):213-28
pubmed: 12445661
PLoS One. 2010 Aug 12;5(8):e12117
pubmed: 20711428
Drug Metab Dispos. 2015 Sep;43(9):1360-71
pubmed: 26149830
Cancer Cell. 2010 Jan 19;17(1):98-110
pubmed: 20129251
N Engl J Med. 2016 Nov 3;375(18):1738-1748
pubmed: 27717303
Cell Stem Cell. 2012 Dec 7;11(6):845-52
pubmed: 23217425
J Clin Oncol. 2017 Nov 10;35(32):3638-3646
pubmed: 28968163
Cancer. 2008 Apr 1;112(7):1575-84
pubmed: 18260157
Breast Cancer Res. 2009;11(5):R77
pubmed: 19874578
J Neurooncol. 2018 Nov;140(2):477-483
pubmed: 30151703
Clin Cancer Res. 2014 Jan 15;20(2):289-95
pubmed: 24270683
J Neurol Neurosurg Psychiatry. 1999 Dec;67(6):763-8
pubmed: 10567494
Oncogene. 2001 Apr 5;20(15):1832-8
pubmed: 11313931
Cancer Chemother Pharmacol. 2009 Sep;64(4):723-32
pubmed: 19169685
Oncol Rep. 2015 Sep;34(3):1549-56
pubmed: 26151768
Oncotarget. 2017 Dec 20;9(10):9540-9554
pubmed: 29507709
Cell Death Discov. 2017 Jul 03;3:17033
pubmed: 28690875
J Pharmacol Exp Ther. 2016 Feb;356(2):354-65
pubmed: 26585571
Mol Cancer Ther. 2014 Mar;13(3):662-74
pubmed: 24362465
Lancet Oncol. 2018 Jul;19(7):904-915
pubmed: 29804902
N Engl J Med. 2005 Mar 10;352(10):997-1003
pubmed: 15758010
Nat Rev Drug Discov. 2015 Feb;14(2):130-46
pubmed: 25633797
Cancer Cell. 2017 Jul 10;32(1):42-56.e6
pubmed: 28697342
Clin Cancer Res. 2013 Feb 15;19(4):764-72
pubmed: 23209033
Mol Pharmacol. 2015 Nov;88(5):846-52
pubmed: 26018905
Oncogene. 2006 Aug 7;25(34):4798-811
pubmed: 16892092
Acta Neuropathol. 2007 Aug;114(2):97-109
pubmed: 17618441
Mol Pharm. 2019 Sep 3;16(9):3842-3852
pubmed: 31329454
Biochimie. 2014 Feb;97:22-7
pubmed: 24139904
Cell Death Dis. 2013 May 16;4:e629
pubmed: 23681224
Int J Cancer. 2006 May 1;118(9):2182-9
pubmed: 16331629
Cancer Cell. 2010 Oct 19;18(4):329-40
pubmed: 20951943
Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1682-6
pubmed: 11172011
Eur J Biochem. 1997 Jan 15;243(1-2):527-36
pubmed: 9030781
Oncogene. 1995 Jul 20;11(2):211-9
pubmed: 7624138
Brain Pathol. 1993 Jul;3(3):255-68
pubmed: 8293185
Br J Neurosurg. 2000 Feb;14(1):28-32
pubmed: 10884881
Front Biosci. 2000 Feb 01;5:D244-57
pubmed: 10704151
Am J Pathol. 2015 Jul;185(7):1820-33
pubmed: 25976245
Cell Cycle. 2012 Mar 15;11(6):1202-16
pubmed: 22391209
Cell Prolif. 2002 Aug;35(4):247-56
pubmed: 12153616
Nat Rev Cancer. 2001 Dec;1(3):222-31
pubmed: 11902577
Gene Ther. 2008 Jan;15(2):117-25
pubmed: 17989702
J Biol Chem. 2009 Oct 30;284(44):30695-707
pubmed: 19737929
Invest New Drugs. 2014 Oct;32(5):825-37
pubmed: 24919854
Cell Cycle. 2004 Feb;3(2):230-4
pubmed: 14712094
Neoplasia. 2007 May;9(5):370-81
pubmed: 17534442
Br J Cancer. 2011 Jun 7;104(12):1862-8
pubmed: 21610706
J Cell Biol. 1996 Apr;133(2):391-403
pubmed: 8609171
J Med Chem. 2009 Aug 27;52(16):5152-63
pubmed: 19603809
Int J Oncol. 2009 Apr;34(4):1051-60
pubmed: 19287962
Nature. 1995 Mar 16;374(6519):280-2
pubmed: 7885450
Blood. 2009 May 7;113(19):4637-45
pubmed: 19234140
Nature. 1999 Dec 9;402(6762):615-22
pubmed: 10604467
Proc Natl Acad Sci U S A. 1999 Feb 2;96(3):1002-7
pubmed: 9927683
Pediatr Blood Cancer. 2007 Apr;48(4):403-7
pubmed: 16609952
Cell. 1986 Apr 11;45(1):145-53
pubmed: 3955656
Acta Neuropathol. 2006 May;111(5):465-74
pubmed: 16557391
Lancet Oncol. 2016 Apr;17(4):425-439
pubmed: 26947331
Cancer Res. 2010 Apr 15;70(8):3228-38
pubmed: 20354191
Mol Cancer Ther. 2010 Aug;9(8):2344-53
pubmed: 20663931
Cell. 1987 Jul 17;50(2):319-25
pubmed: 3297353
Cell Cycle. 2003 May-Jun;2(3):243-50
pubmed: 12734434
Int J Cancer. 2019 Jul 1;145(1):242-253
pubmed: 30549269
Oncogene. 1999 Sep 20;18(38):5311-7
pubmed: 10498883
Cell Death Differ. 2010 Jul;17(7):1189-98
pubmed: 20111042
Nature. 2008 Oct 23;455(7216):1061-8
pubmed: 18772890
Clin Cancer Res. 2018 Mar 1;24(5):1124-1137
pubmed: 29254993
Cell Stem Cell. 2013 Jan 3;12(1):88-100
pubmed: 23260487
PLoS One. 2010 Sep 03;5(9):e12548
pubmed: 20838435
Cancer Cell Int. 2016 Nov 18;16:88
pubmed: 27891063
J Cell Biochem. 2006 Oct 15;99(3):978-85
pubmed: 16741970
J Biol Chem. 2010 Nov 12;285(46):35728-39
pubmed: 20810654
Cancer Cell. 2006 Mar;9(3):157-73
pubmed: 16530701
Annu Rev Cell Dev Biol. 1997;13:261-91
pubmed: 9442875
Mol Cancer Ther. 2003 Feb;2(2):139-50
pubmed: 12589031
Cancer Res. 1996 Jul 1;56(13):2973-8
pubmed: 8674031
J Clin Oncol. 2006 Jun 1;24(16):2563-9
pubmed: 16735709
EMBO Rep. 2010 Nov;11(11):876-82
pubmed: 20930849
J Biol Chem. 2008 Mar 21;283(12):7721-32
pubmed: 18216018
Nat Med. 1998 Oct;4(10):1103-6
pubmed: 9771732
Br J Pharmacol. 2013 May;169(1):156-66
pubmed: 23347136
Sci Rep. 2019 Mar 21;9(1):5012
pubmed: 30899038
Nature. 1995 Mar 16;374(6519):283-7
pubmed: 7533895
J Clin Oncol. 2018 Aug 20;36(24):2465-2472
pubmed: 29860922
Science. 1996 Dec 6;274(5293):1672-7
pubmed: 8939849
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Expert Opin Investig Drugs. 2013 Jun;22(6):723-38
pubmed: 23647051
Am J Physiol Cell Physiol. 2015 Feb 15;308(4):C339-47
pubmed: 25500740
J Clin Oncol. 2017 Sep 1;35(25):2875-2884
pubmed: 28580882
Development. 2013 Aug;140(15):3079-93
pubmed: 23861057
Genes Dev. 1998 Feb 1;12(3):285-9
pubmed: 9450924
J Cancer Res Ther. 2016 Apr-Jun;12(2):811-7
pubmed: 27461656
Mol Cell. 1998 Jul;2(1):43-53
pubmed: 9702190
Science. 2014 Jan 10;343(6167):189-193
pubmed: 24336570